Press Release Archives - Page 19 of 19 - Spherix Global Insights

Invest in intelligence that delivers

Neurology, Press Release

With Novartis’ Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono’s Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure

June 26, 2019

Bolstering Tecfidera’s competitiveness with the glatiramer acetate class among treatment-naïve relapsing-remitting multiple sclerosis patients is Biogen’s best defense against anticipated

US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia’s Auryxia, Amgen’s Parsabiv, and Opko’s Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products

June 25, 2019

According to the latest quarterly update from Spherix Global Insights, strict protocols at large dialysis organizations (LDOs) are the leading

Sanofi/Regeneron’s Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment

November 7, 2018

With Dupixent only capturing a piece of the potential candidate pie, there remains ample runway for new agents in development

In Multiple Myeloma, Janssen’s Darzalex Posted Significant Gains Over the Past Six Months, but May Face an Increasingly Restrictive Payer Environment

October 31, 2018

According to a new report from Spherix Global Insights, provider reimbursement anxiety and escalating out-of-pocket costs, as patients live longer

Uptake of Biogen’s Tecfidera and Increased Availability of Merck KGaA’s Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva’s Copaxone

October 9, 2018

Lack of access to Roche’s Ocrevus for primary progressive multiple sclerosis has stymied UK prescriber base growth and adoption over

More Rheumatologists are Using Pfizer’s Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly’s Taltz in the Previous Quarter

October 8, 2018

Download Report Overview EXTON, Pa., Oct. 8, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by

Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron’s Dupixent

September 27, 2018

Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer’s PF-0496582, AbbVie’s upadacitinib and Incyte’s topical ruxolitinib have

Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report

September 21, 2018

From: Multiple Sclerosis News Today By: Alice Melao

Ocrevus Predicted to Be a Billion-dollar Blockbuster

September 4, 2018

From: Multiple Sclerosis News Today By: Ed Tobias The research firm Spherix Global Insights, which analyzes trends in the pharmaceutical

Biosimilars in Nephrology: Pfizer’s Retacrit Gets FDA Clearance and Prepares to Challenge Amgen’s Anemia Franchise Head On

May 31, 2018

The latest quarterly anemia report from Spherix Global Insights indicates a receptive audience for biosimilar erythropoietin stimulating agents (ESAs), but

TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population

May 30, 2018

According to Spherix Global Insights, data from over 1,000 psoriatic arthritis patients who recently switched therapies reveals that clinical factors,

Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights

April 9, 2018

Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to